- Home
- ACHC vs YDES Comparison
ACHC vs YDES Comparison
Compare ACHC & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACHC | YDES |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACHC | YDES |
|---|---|---|
| Price | $13.62 | $11.50 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $20.07 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 65.1K |
| Earning Date | 02-26-2026 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $3,265,548,000.00 | $510,360.00 |
| Revenue This Year | $6.44 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | 4.58 | ★ 45.76 |
| 52 Week Low | $11.43 | $5.30 |
| 52 Week High | $45.47 | $31.00 |
Technical Indicators
Market Signals| Indicator | ACHC | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 42.16 |
| Support Level | $12.97 | $11.74 |
| Resistance Level | $13.67 | $12.00 |
| Average True Range (ATR) | 0.98 | 0.73 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 50.46 | 3.50 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.